The diagnosis of a disease normally depends on the risk factors one is exposed to during his or her lifetime, and subsequently therapeutic measures are taken in order to treat the same with hopes of a better prognosis and a healthy lifestyle. However, scientists at the Brigham and Women’s Hospital…
For years, clinicians and patients could only notice and accept the fact that four times more women than men are diagnosed with multiple sclerosis. Now, a group of researchers from Washington University School of Medicine in St. Louis are uncovering a potential reason for the disparity, and they recently…
A small scale study undertaken by researchers at the Department of Neurology, Oregon Health & Science University (OSHU) showed the benefits of maintaining a low-fat diet in improving fatigue related to multiple sclerosis (MS). The study was led by Dr. Vijayshree Yadav, M.D., an associate professor of neurology in…
One of the most common and troublesome symptoms of multiple sclerosis is spasticity. Patients with spasticity experience involuntary muscle spasms and muscle stiffness, which interfere with daily activities. An imbalance in the signals from the brain and spinal cord in the central nervous system increase the excitability of muscles,…
Although the biological activity by which Copaxone (glatiramer) exerts its effects i multiple sclerosis (MS) patients is not fully understood, it is believed it can block the induction of autoimmune encephalomyelitis as observed in recent experiments with mice. Research in animals and in vitro systems suggest that glatiramer acetate-specific suppressor…
New research work from GlaxoSmithKline presented by Daren Ausin, PhD, at the American Academy of Neurology’s 66th Annual Meeting has implications for individuals with relapsinig-remitting multiple sclerosis. The presentation detailed a study that used GlaxoSmithKline’s ofatumumab in 231 patients with relapse-remitting multiple sclerosis. Ofatumumab is an anti-B-cell antibody, and it…
The National Center of Neurology and Psychiatry, based in Japan, announced that they will initiate a 3-month clinical trial on 9 patients with multiple sclerosis, beginning in March. Multiple sclerosis is an autoimmune disease caused by mutations of lymphocyte immune cells, which attack and destroy a patient’s own nerve cells. Patients with multiple sclerosis typically…
Marijuana has been approved for medicinal purposes in a number of U.S. states, however it still remains a much debated issue according to the American Academy of Neurology. New information has been released by ANN Annual Meeting in Philadelphia, PA. This represents the largest gathering of neurologists globally. According…
Nerve cells are notoriously difficult to regenerate, but according to a recent article in Science Daily, a research group from University of Galgary’s Hotchkiss Brain Institute (HBI) has discovered a new way to turn on neural cell growth, which would be beneficial for treating nerve damage commonly found in diseases…
Petah Tikvah Israel-based Teva Pharmaceutical Industries Ltd. has suffered a setback in its fight to forestall release of generic competitors for its proprietary Copaxone Multiple Sclerosis drug. However, the company is expressing optimism that potential for recovery of Patent Infringement Damages may dissuade aspirant generic competitors from proceeding until a…
Get regular updates to your inbox.